Tips for Evolving Medicaid Pharmacy Benefits Management (PBM) Programs. June 5, 2015

Size: px
Start display at page:

Download "Tips for Evolving Medicaid Pharmacy Benefits Management (PBM) Programs. June 5, 2015"

Transcription

1 Tips for Evolving Medicaid Pharmacy Benefits Management (PBM) Programs 1 June 5, 2015

2 Introductions Mark Steck Pharm.D Independent Consultant, MAXIMUS John J.P. Crouse Vice President, MAXIMUS Market Lead DecisionPoint for Pharmacy Benefits Management 2

3 Agenda Introductions Changes in the Medicaid Population Increasing Drug Costs Changing Technology Prescription Drug Abuse Strategies for States 3

4 Changes in Medicaid Populations The Medicaid population is growing and changing Total Medicaid & CHIP enrollment has grown by 19% since 2013 to over nearly 70 million people This is through both expansion and woodwork affect Fiscal 2011 data (the most current data available) Disabled 15% Elderly 9% Adults - 27% Children - 48% 4

5 Changes in Medicaid Populations States that have expanded Medicaid have brought new populations to the Program Childless Adult populations have brought with them a number of special cases that Medicaid had not traditionally dealt with in large numbers Hepatitis C, HIV\AIDS, Tuberculosis Some cancers Drug spend that was part of public health is now paid for by the Medicaid program 5

6 Changes in Medicaid Populations States have moved many enrollees to Medicaid Managed Care plans Nationally, nearly 75% of the Medicaid population now receives their medical services, and their prescription drug benefit, through a Managed Care Organization (MCO) Each MCO is free to manage their PBM program as they wish, within some limits percent of people covered by Medicaid now in some kind of managed care 6

7 Increasing Drug Costs Data and Trends Utilization Nationwide Part D Medicaid 1. Lipid Regulators 2. Antidepressants 3. Narcotic Analgesics 4. Beta Blockers 5. ACE Inhibitors 6. Antidiabetics 7. Respiratory Agents 11. Tranquilizers 12. Thyroid Preps 13. Calcium Antagonists 14. Antirheumatics 15. Hormonal Contraceptives 16. Angiotensin II Blockers 17. Penicillins 1. Lipid Regulators 2. ACE Inhibitors 3. Calcium Channel Blockers 4. Beta Blockers 5. Proton Pump Inhibitors 6. Thyroid Preps 7. Angiotensin II Blockers 1. Antipsychotics 2. CNS Stimulants 3. Narcotic Analgesics 4. Anticonvulsants 5. Diabetic Agents 6. Anxiolytic / Hypnotics 8. Anti Ulcerants 18. Macrolides 8. Narcotic Analgesics CDC Diuretics 19. Vitamins/Minerals 9. Antidepressants 10. Seizure Disorder Agents 20. Hypnotic / Sedatives 10. Seizure Disorders IMS 2015 CBO

8 Increasing Drug Costs Miscellaneous Information $300 Billion in U.S. Spending Drugs as a Percent of Healthcare Spend Nationally % Medicaid 5% Costs Spiked in % largest increase since 2003 Dispensing rates for generic drugs are similar across Medicaid FFS and Medicare Part D Drug costs are lower in Medicaid FFS than in Medicare Part D because of CMS rebates Average Cost of Drugs for Top 50 Therapeutic Classes (70% of Drug Spend) for 30 Day Supply Part D: $50 Medicaid FFS: $37 CMS Rebate Brand Drugs 23.1% Generics (and other limited categories) 13.0% Specialty Drugs in Medicaid: 2% of the Utilization / 32% of the Spend Generic Drugs: Top Ten Therapeutic Classes Rose Over 400% in

9 Increasing Drug Costs Specialty Pharmacy 9

10 Increasing Drug Costs Specialty Pharmacy RANKED BY 2014 PMPY SPEND Trend Therapeutic Class PMPY Util. Unit Cost Total 1 Inflammatory Conditions $ % 15.7% 24.3% 2 Multiple Sclerosis $ % 9.7% 12.9% 3 Oncology $ % 11.7% 20.7% 4 Hepatitis C $ % 666.6% 742.6% 5 HIV $ % 10.3% 14.8% 6 Misc. Specialty Conditions $ % 8.2% 35.6% 7 Growth Deficiency $ % 7.5% 6.6% 8 Hemophilia $ % 17.6% 16.9% 9 Pulmonary Arterial HTN $ % 6.2% 13.8% 10 Transplant $ % -3.1% -2.3% TOTAL Specialty $ % 25.2% 30.9% *Am J Health-Syst Pharm. 2014; 71:e

11 Increasing Drug Costs Specialty Pharmacy Specialty Drug Sampling Afatinib (Gilotrif )* Dabrafenib (Tafinlar)* Ibrutinib (Imbruvica)* Drugs Approved in 2013 / 2014 Drug Indication Cost Obinutuzumab (Gazyva)* Trametinib (Mekinist)* First-line metastatic non-small cell lung cancer with an EGFR mutation Unresectable or metastatic melanoma with BRAF V600E mutation Pts. with mantle cell lymphoma who have received at least 1 prior therapy Previously untreated chronic lymphocytic leukemia (with chlorambucil) Unresectable or metastatic melanoma with BRAF V600E mutation 11 $6,300/mo $8,600/mo $12,500/mo $12,400/mo $9,800/mo Opdivo PD-1 inhibitor $143,000/yr Sovaldi Hep-C $84K- $168K/tx Kalydeco Cystic Fibrosis $300,000/yr *Am J Health-Syst Pharm. 2014; 71:e6-23

12 Increasing Generic Drug Costs Almost 80% of all prescriptions dispensed as generics Cost 7,000-8,000% increases over a couple months Reasons Excuses Consolidation Raw material shortages Production run interruptions Q&A and compliance issues Bottom line: competition, it has always driven generic pricing Cost increases dramatic, but equally problematic is the velocity of the increases Impact on pharmacies Timeliness of pricing Purchase price versus reimbursement rate Access Issue (patients sent away from pharmacies) 12

13 Changing Technology PBM technology is fairly mature eprescribing is now pervasive and electronically transmitted prescriptions now account for roughly half of all prescriptions The next significant technology change that is emerging in the market is Electronic Prior Authorization (epa) epa has the potential to substantially change the workflow for filling prescriptions for non-preferred drugs Implementing epa allows PBMs to receive Prior Authorization requests generated within the prescribers Electronic Health Records (EHR) systems. 13

14 Prescription Drug Abuse Prescription drug abuse is a national problem that touches Medicaid program as well as all public and private health systems. Drug overdose is now the leading cause of death in some states surpassing motor vehicle accidents Medicaid programs are addressing the issue through utilization and fraud management and participation in State Prescription Drug Monitoring Programs (PDMP) 14

15 Strategies for States The Changing Role of the PBM in Medicaid Historically Through the Late 1990s: Fiscal Intermediary Role Claims Processing Rebate Processing OBRA 90 RetroDUR Early 2000s: Management of the Actual Benefit Care Management Initiatives Preferred Drug List Now Environmental Shift Changing Role Modularized MMIS Increased Managed Care Enrollment New Medical Approaches New Challenges Extension of State Medicaid Pharmacy Departments Emphasis on Program Performance Evaluation (Across FFS & MCO) Increased Need for Enhanced Analytics 15

16 Strategies for States Specialty Pharmacy Cost justifies individual and sub-population strategy Approach includes: Case identification Educational resources access and outreach through a Treatment Information Center Distribution management System edits/monitoring Compliance and Clinical Value Monitoring Provider contracting Limited network reduced reimbursement rate 1915(b)(4) Supplemental rebates (more efficient access greater profit opportunity) 16

17 Strategies for States Generic Drugs Access Improve/eliminate timing issue, access will improve Wholesaler contracting Agree to inventory levels Agree to price increase restraints Agree to restricted contracting Direct purchasing Supplemental rebates Direct purchasing Issue with limited access by providers Tipping point and mutual interest Administration analytics, monitoring, contracting 17

18 Strategies for States Statewide PDL / SR Preferred Drug List (Formulary) Currently MCOs Have Their Own Formularies Creates Difficulties and Administrative Challenges to Enforce Consistency and Compliance Statewide PDL Increases Rebates, Decreases Issues with Consistency Supplemental Rebates Based on PDL Above and Beyond CMS Rebates Individual MCO Formularies Fragment Buying Power (i.e., Lower Rebates) 1-2% vs 7%-8% Push Back MCOs Commercial PBMs Manufacturers 18

19 Questions Discussion 19

20 Thank You! To view the recording of this webinar and others, please visit: 20

MArch The 2014 Drug Trend Report Highlights

MArch The 2014 Drug Trend Report Highlights MArch 2015 The 2014 Drug Report Highlights Highest Increase in U.S. Drug Spend Over Past Decade In 2014, the pharmacy landscape underwent a seismic change, and the budgetary impact to healthcare payers

More information

Magellan Rx. A smarter approach to pharmacy benefits management

Magellan Rx. A smarter approach to pharmacy benefits management Magellan Rx A smarter approach to pharmacy benefits management Presented by: Cheri Caruso, VP of Sales, Magellan Rx Management Bryce Canfield, VP, Client Development, GoodRx A unique vision of care We

More information

April 2o14. The 2013 Drug Trend Report Highlights

April 2o14. The 2013 Drug Trend Report Highlights April 2o14 The 2013 Drug Trend Report Highlights Express Scripts Reports Lowest Specialty Drug Trend Since 2007 In 2013, spending on prescription drugs increased 5.4% after several years of slower-paced

More information

Idaho DUR Board Meeting Minutes

Idaho DUR Board Meeting Minutes Idaho DUR Board Meeting Minutes Date: July 20, 2017 Time: 9am-12:30pm Location: Holiday Inn Boise Airport 2970 West Elder Street, Boise, Idaho, 83705 Moderator: David Agler, M.D. Committee Member Present:

More information

Prescription Drugs North Carolina Policies. Carol Steckel, MPH Medicaid Director

Prescription Drugs North Carolina Policies. Carol Steckel, MPH Medicaid Director Prescription Drugs North Carolina Policies Carol Steckel, MPH Medicaid Director March 19, 2013 Pharmacy Services Optional service provided each year to about 1.5 million beneficiaries by 2,200 pharmacy

More information

Texas Vendor Drug Program. Formulary Drug Index File Layout. Layout effective: Jul. 2, 2018 Document update: Oct. 1, 2018

Texas Vendor Drug Program. Formulary Drug Index File Layout. Layout effective: Jul. 2, 2018 Document update: Oct. 1, 2018 Texas Vendor Drug Program Formulary Drug Index File Layout Layout effective: Jul. 2, 2018 Document update: Oct. 1, 2018 The Vendor Drug Program provides a weekly update of resource data available for download

More information

Medication trends shaping workers compensation. A 2018 update of the prevailing industry influences impacting pharmacy outcomes

Medication trends shaping workers compensation. A 2018 update of the prevailing industry influences impacting pharmacy outcomes Medication trends shaping workers compensation A 2018 update of the prevailing industry influences impacting pharmacy outcomes This page intentionally left blank Trends impacting workers compensation pharmacy

More information

Legislative & Regulatory Update Brad Young, RxPlus Government Affairs

Legislative & Regulatory Update Brad Young, RxPlus Government Affairs Legislative & Regulatory Update 2018 Brad Young, RxPlus Government Affairs Disclosures Brad Young reports no actual or potential conflicts of interest associated with this presentation. 2 Learning Objectives

More information

Medicaid Perspective

Medicaid Perspective Prescription Opioid Fraud and Abuse: Medicaid Perspective Presenter: Gary P. Gilmore, B.S., R.Ph. Director, Analysis & Reporting Office of Clinical Affairs Deputy Director, Pharmacy Program Objectives:

More information

Texas Vendor Drug Program. Formulary Delimited File Layout. April 26, 2017

Texas Vendor Drug Program. Formulary Delimited File Layout. April 26, 2017 Texas Vendor Drug Program Formulary Delimited File Layout April 26, 2017 The Vendor Drug Program provides a weekly update of resource data available for download from txvendordrug.com/resources/downloads.

More information

2017 Drug Trend Report Commercial Medicare Medicaid Exchanges

2017 Drug Trend Report Commercial Medicare Medicaid Exchanges 2017 Drug Trend Report Commercial Medicare Medicaid Exchanges Leading the way for patients and plans Our clients place a great deal of trust in Express Scripts. They ask us to care for their plan members

More information

Market Distortions from the 340B Drug Pricing Program

Market Distortions from the 340B Drug Pricing Program Market Distortions from the 340B Drug Pricing Program Adam J. Fein, Ph.D. www.drugchannels.net @DrugChannels The opinions and views expressed in this presentation are those of the author and may not reflect

More information

Medicaid in South Carolina. South Carolina Medicaid in /19/2018. > FY 2017 Appropriation: $7.2 billion > Full benefit Membership: 1.

Medicaid in South Carolina. South Carolina Medicaid in /19/2018. > FY 2017 Appropriation: $7.2 billion > Full benefit Membership: 1. Medicaid in South Carolina > FY 2017 Appropriation: $7.2 billion > Full benefit Membership: 1.04 million South Carolina Medicaid in 2018 Bryan Amick SC Chapter, American Academy of Pediatrics 2018 CATCH

More information

Risk Classification Modeling to Combat Opioid Abuse

Risk Classification Modeling to Combat Opioid Abuse Risk Classification Modeling to Combat Opioid Abuse Improve Data Sharing to Identify High-Risk Prescribers of Opioids Christopher Sterling Chief Statistician NCI, Inc. www.nciinc.com 11730 Plaza America

More information

Idaho DUR Board Meeting Minutes

Idaho DUR Board Meeting Minutes Idaho DUR Board Meeting Minutes Date: October 16, 2014 Time: 9am-2pm Location: Idaho Medicaid, 3232 Elder Street, Boise, Idaho, Conference Room D-West Moderator: Mark Turner, M.D. Committee Member Present:

More information

The Un-Special World of Specialty Medications

The Un-Special World of Specialty Medications The Un-Special World of Specialty Medications Manpreet Chahal, PharmD, PhD Oncology Pharmacist, Medical Oncology Associates, Spokane WA Adjunct Clinical Instructor, WSU College of Pharmacy mschahal@wsu.edu

More information

THE GROWTH OF SPECIALTY PHARMACY

THE GROWTH OF SPECIALTY PHARMACY UnitedHealth Center for Health Reform & Modernization THE GROWTH OF SPECIALTY PHARMACY Current trends and future opportunities Issue Brief April 2014 Summary Innovative specialty drugs are providing important

More information

Note: Mandatory measures are those measures that are a requirement of accreditation and must be reported to URAC on an annual basis.

Note: Mandatory measures are those measures that are a requirement of accreditation and must be reported to URAC on an annual basis. COMMUNITY PHARMACY V1.1 MANDATORY S Note: Mandatory measures are those measures that are a requirement of accreditation and must be reported to URAC on an annual basis. # NAME DESCRIPTION NUMERATOR DENOMINATOR

More information

9/25/15. Pharmacy Quality Measures: Financial Support. Learning Objectives. Speaker Disclosure. Access to Preferred Networks and Clinical Performance

9/25/15. Pharmacy Quality Measures: Financial Support. Learning Objectives. Speaker Disclosure. Access to Preferred Networks and Clinical Performance Pharmacy Quality Measures: Action Steps for Improvement Financial Support Financial support was provided for this activity through an unrestricted grant from Health Mart Systems, Inc. Christine Jacobson

More information

Evaluation of Specialty Pharmacy in an Integrated Health-System

Evaluation of Specialty Pharmacy in an Integrated Health-System Evaluation of Specialty Pharmacy in an Integrated Health-System Emma Chermely, PharmD, BCACP Alyssa McCann, PharmD, BCACP *The presenters have no conflicts of interest to disclose. Objectives Introduce

More information

Chapter 6: Healthcare Expenditures for Persons with CKD

Chapter 6: Healthcare Expenditures for Persons with CKD Chapter 6: Healthcare Expenditures for Persons with CKD In this 2017 Annual Data Report (ADR), we introduce information from the Optum Clinformatics DataMart for persons with Medicare Advantage and commercial

More information

Opioid Use and Misuse: History, Trends, And The Oregon Opioid Initiative

Opioid Use and Misuse: History, Trends, And The Oregon Opioid Initiative Opioid Use and Misuse: History, Trends, And The Oregon Opioid Initiative John W. McIlveen, Ph.D., LMHC, State Opioid Treatment Authority, Oregon Health Authority, Addictions and Mental Health Division

More information

Drug Prior Authorization Form Opdivo (nivolumab)

Drug Prior Authorization Form Opdivo (nivolumab) This document contains both information and form fields. To read information, use the Down Arrow from a form field. Drug Prior Authorization Form The purpose of this form is to obtain information required

More information

Statement Of. The National Association of Chain Drug Stores. For. U.S. Senate Committee on Finance. Hearing on:

Statement Of. The National Association of Chain Drug Stores. For. U.S. Senate Committee on Finance. Hearing on: Statement Of The National Association of Chain Drug Stores For U.S. Senate Committee on Finance Hearing on: 10:00 a.m. National Association of Chain Drug Stores (NACDS) 1776 Wilson Blvd., Suite 200 Arlington,

More information

Managing Opioid Overutilization Challenges

Managing Opioid Overutilization Challenges One Source. Lower Cost. Better Care. Managing Opioid Overutilization Challenges A LOOK AT REDUCING OPIOID OVERUTILIZATION BY 36 PERCENT Copyright 2017 MedImpact Healthcare Systems, Inc. All rights reserved.

More information

Session 169 L, Quantifying Excess Specialty Drug Risk. Moderator: Patrick Gallagher, FSA, FCAS. Presenters: Robert Bachler, FSA, FCAS, MAAA

Session 169 L, Quantifying Excess Specialty Drug Risk. Moderator: Patrick Gallagher, FSA, FCAS. Presenters: Robert Bachler, FSA, FCAS, MAAA Session 169 L, Quantifying Excess Specialty Drug Risk Moderator: Patrick Gallagher, FSA, FCAS Presenters: Patrick Gallagher, FSA, FCAS Robert Bachler, FSA, FCAS, MAAA SOA Antitrust Disclaimer SOA Presentation

More information

2017 Drug Trends Series

2017 Drug Trends Series 2017 Drug Trends Series Part 1 Evaluating the traditional view Retail and mail-order prescriptions Published April 2018 1 2017 Drug Trends Series Traditional View First Script A year of important progress

More information

The Risky Business of Claims-Only Risk Adjustments

The Risky Business of Claims-Only Risk Adjustments The Risky Business of Claims-Only Risk Adjustments August 3 rd & 4 th, 2016 Presented by: Kim Browning Executive Vice President Vince Bryant Vice President of Business Development Agenda 2 Plan Selection

More information

PBMs: Impact on Cost and Quality of Pharmaceutical Care in the U.S.

PBMs: Impact on Cost and Quality of Pharmaceutical Care in the U.S. Speaker Brian K. Solow, MD, FAAFP Optum Life Sciences Irvine, CA, USA PBMs: Impact on Cost and Quality of Pharmaceutical Care in the U.S. Brian K. Solow, MD, FAAFP Chief Medical Officer, Optum Life Sciences

More information

Innovative Ways to Fund Harm Reduction Services New Mexico

Innovative Ways to Fund Harm Reduction Services New Mexico Innovative Ways to Fund Harm Reduction Services New Mexico Laine M. Snow, MSW HIV Service Program Manager New Mexico Department of Health History and Importance of Harm Reduction New Mexico Sero-prevalence

More information

Cost of Mental Health Care

Cost of Mental Health Care Section 4 Cost of Mental Health Care Per capita mental health spending for Americans with a mental health diagnosis has increased among children, peaking in. For adults, the spending has been more stable.

More information

2017 URAC PHARMACY BENEFIT MANAGEMENT PERFORMANCE MEASUREMENT: AGGREGATE SUMMARY PERFORMANCE REPORT

2017 URAC PHARMACY BENEFIT MANAGEMENT PERFORMANCE MEASUREMENT: AGGREGATE SUMMARY PERFORMANCE REPORT 2017 URAC PHARMACY BENEFIT MANAGEMENT PERFORMANCE MEASUREMENT: AGGREGATE SUMMARY PERFORMANCE REPORT December 2017 Table of Contents Executive Summary... 1 Pharmacy Benefit Management Organization Characteristics...

More information

using analytics to identify and strategically manage patient opioid abuse

using analytics to identify and strategically manage patient opioid abuse using analytics to identify and strategically manage patient opioid abuse Philip Finocchiaro, MD, FACP Senior Medical Director, Quality and Clinical Outcomes Verscend Olivia Mapplethorpe Senior Client

More information

2125 Rayburn House Office Building 2125 Rayburn House Office Building Washington, DC Washington, DC 20515

2125 Rayburn House Office Building 2125 Rayburn House Office Building Washington, DC Washington, DC 20515 The Honorable Greg Walden Chairman Ranking Member 2125 Rayburn House Office Building 2125 Rayburn House Office Building Washington, DC 20515 Washington, DC 20515 Chairman Ranking Member Subcommittee on

More information

How to Conduct an Effective Medication Therapy Management Session in the Community Pharmacy

How to Conduct an Effective Medication Therapy Management Session in the Community Pharmacy How to Conduct an Effective Medication Therapy Management Session in the Community Pharmacy Presented by: Dale Christensen, University of North Carolina Susmita Chavala, Humana Ed Staffa, Community MTM

More information

Evaluation of a Medicaid Psychotropic Drug Management Program in Utah

Evaluation of a Medicaid Psychotropic Drug Management Program in Utah Evaluation of a Medicaid Psychotropic Drug Management Program in Utah Dominick Esposito James M. Verdier 2008 SAMHSA/CMS Invitational Conference on Medicaid and Mental Health Service/Substance Abuse Treatment

More information

Restrictions to HCV Treatment in State Medicaid Programs

Restrictions to HCV Treatment in State Medicaid Programs Center for Health Law and Policy Innovation of Harvard Law School Restrictions to HCV Treatment in State Medicaid Programs Acknowledgements: We are in the midst of merging/comparing data with other analysts

More information

Texas Vendor Drug Program. Pharmacy Provider Procedure Manual. Vitamin and Mineral Products. Effective Date. November 2017

Texas Vendor Drug Program. Pharmacy Provider Procedure Manual. Vitamin and Mineral Products. Effective Date. November 2017 Texas Vendor Drug Program Pharmacy Provider Procedure Manual Vitamin and Mineral Products Effective Date November 2017 The Pharmacy Provider Procedure Manual (PPPM) is available online at txvendordrug.com/about/policy/manual.

More information

Clinical Therapeutic Intelligence Report: Year in Review

Clinical Therapeutic Intelligence Report: Year in Review Clinical Therapeutic Intelligence Report: Year in Review Last year marked a productive year for oncology drug research and development with ten new oncology drugs coming to market two of which were granted

More information

2016 Drug Trends Series

2016 Drug Trends Series Drug Trends Series Part 3: Assessing opioids and compounds Published August 2017 1 Drug Trends Series Opioids & Compounds First Script Introduction As with the first two editions in Coventry s Drug Trends

More information

Note: Mandatory measures are those measures that are a requirement of accreditation and must be reported to URAC on an annual basis.

Note: Mandatory measures are those measures that are a requirement of accreditation and must be reported to URAC on an annual basis. Note: Mandatory measures are those measures that are a requirement of accreditation and must be reported to URAC on an annual basis. DESCRIPTION NUMERATOR DENOMINATOR DM2012-12 Portion of Days Covered

More information

Medication Therapy Management: Improving Health and Saving Money

Medication Therapy Management: Improving Health and Saving Money Medication Therapy Management: Improving Health and Saving Money Ed Staffa, RPh Vice President, Pharmacy Mirixa Corporation estaffa@mirixa.com July 23, 2008 MTM At A Glance The U.S. health care system

More information

Chairwoman Bono Mack, Vice-Chairwoman Blackburn, Ranking Member Butterfield and

Chairwoman Bono Mack, Vice-Chairwoman Blackburn, Ranking Member Butterfield and United States House of Representatives Committee on Energy and Commerce Subcommittee on Commerce, Manufacturing and Trade Hearing on Chairwoman Bono Mack, Vice-Chairwoman Blackburn, Ranking Member Butterfield

More information

Illinois Prescription Monitoring Program. Sarah Pointer, Pharm D. Clinical Director of the Illinois Prescription Monitoring Program

Illinois Prescription Monitoring Program. Sarah Pointer, Pharm D. Clinical Director of the Illinois Prescription Monitoring Program Illinois Prescription Monitoring Program Sarah Pointer, Pharm D. Clinical Director of the Illinois Prescription Monitoring Program Agenda Provide an overview of the Illinois Prescription Monitoring Program

More information

Changes to the Eighth Edition

Changes to the Eighth Edition Pharmacy Practice and the Law, Eighth Edition Includes Navigate 2 Advantage Access By Richard R. Abood, BS Pharm, JD-Professor Emeritus Pharmacy Practice, Thomas J. Long School of Pharmacy and Health Sciences,

More information

The University of Mississippi School of Pharmacy

The University of Mississippi School of Pharmacy LONG TERM PERSISTENCE WITH ACEI/ARB THERAPY AFTER ACUTE MYOCARDIAL INFARCTION: AN ANALYSIS OF THE 2006-2007 MEDICARE 5% NATIONAL SAMPLE DATA Lokhandwala T. MS, Yang Y. PhD, Thumula V. MS, Bentley J.P.

More information

Kentucky Department for Medicaid Services. Drug Review Options

Kentucky Department for Medicaid Services. Drug Review Options Kentucky Department for Medicaid Services Drug Review Options The following chart lists the agenda items scheduled and the options submitted for review at the November 21, 2013 meeting of the Pharmacy

More information

Coding for Care: Using Data Analytics for Risk Adjustment. March 2, 2016 Clive Fields, MD, President, Village Family Practice

Coding for Care: Using Data Analytics for Risk Adjustment. March 2, 2016 Clive Fields, MD, President, Village Family Practice Coding for Care: Using Data Analytics for Risk Adjustment March 2, 2016 Clive Fields, MD, President, Village Family Practice Conflict of Interest Clive Fields, MD, has no real or apparent conflicts of

More information

E-Prescribing, EPCS & PDMP: An Update

E-Prescribing, EPCS & PDMP: An Update E-Prescribing, EPCS & PDMP: An Update Melissa A. Kotrys, MPH Chief Executive Officer July 27, 2018 Arizona Health-e Connection is now Health Current Arizona s primary resource for health information technology

More information

The Prescription Drug Overdose Epidemic

The Prescription Drug Overdose Epidemic The Prescription Drug Overdose Epidemic Rita Noonan, PhD National Center for Injury Prevention and Control Centers for Disease Control and Prevention National Center for Injury Prevention and Control Division

More information

Massachusetts Department of Developmental Services Medication Review

Massachusetts Department of Developmental Services Medication Review University of Massachusetts Medical School escholarship@umms Commonwealth Medicine Publications Commonwealth Medicine 8-7-2012 Massachusetts Department of Developmental Services Medication Review Alexandra

More information

Deconstructing the RADV: The Past, Present, and Future of RADV

Deconstructing the RADV: The Past, Present, and Future of RADV Deconstructing the RADV: The Past, Present, and Future of RADV May 24, 2016 Presented by: Kim Browning, CHRS, PMP, CHC Executive Vice President Agenda 2 PY 2007 What We ve Learned PY 2011 Expectations

More information

Executive Summary. Classes Under Review: Analysis:

Executive Summary. Classes Under Review: Analysis: Outcome Report on MHQAC Edits Classes Under Review: Analysis: Atypical Antipsychotics, SSRIs, SNRIs, Antianxietals, Hypnotics, and Drugs to Treat ADD/ADHD Utilization and Cost Trends: Pre and Post Implementation

More information

Statement Of. The National Association of Chain Drug Stores. For. U.S. House of Representatives Committee on the Budget.

Statement Of. The National Association of Chain Drug Stores. For. U.S. House of Representatives Committee on the Budget. Statement Of The National Association of Chain Drug Stores For U.S. House of Representatives Committee on the Budget Hearing on: 2:00 p.m. 210 Cannon House Office Building National Association of Chain

More information

Submitted to the House Energy and Commerce Committee. Federal Efforts to Combat the Opioid Crisis

Submitted to the House Energy and Commerce Committee. Federal Efforts to Combat the Opioid Crisis STATEMENT FOR THE RECORD Submitted to the House Energy and Commerce Committee Federal Efforts to Combat the Opioid Crisis October 25, 2017 America s Health Insurance Plans 601 Pennsylvania Avenue, NW Suite

More information

Tri-County Region Opioid Trends Clackamas, Multnomah, and Washington, Oregon. Executive Summary

Tri-County Region Opioid Trends Clackamas, Multnomah, and Washington, Oregon. Executive Summary Tri-County Region Opioid Trends Clackamas, Multnomah, and Washington, Oregon 2016 Executive Summary 20.8 million people in the United States have a substance use disorder (not limited to opioids), equivalent

More information

Massachusetts Department of Developmental Services. Medication Review

Massachusetts Department of Developmental Services. Medication Review Massachusetts Department of Developmental Services Medication Review NASDDDS Reinventing Quality August 7, 2012 Alixe Bonardi 1, Gail Grossman 2 Emily Lauer 1 1 University of Massachusetts Medical School

More information

MEASURE STEWARD Pharmacy Quality Alliance (PQA) D ATA SOURCE Enrollment; U R A C DOMAIN Engagement & Experience of Care

MEASURE STEWARD Pharmacy Quality Alliance (PQA) D ATA SOURCE Enrollment; U R A C DOMAIN Engagement & Experience of Care MANDATORY S Note: Mandatory measures are those measures that are a requirement of accreditation and must be reported to URAC on an annual basis. DM2012-12 DTM2015-01 Portion of Days Covered (PDC) Adherence

More information

Summary of Related Documentation Pennsylvania House Bill 1846 of 2014

Summary of Related Documentation Pennsylvania House Bill 1846 of 2014 Summary of Related Documentation Pennsylvania House Bill 1846 of 2014 15 November 2018 Department of Labor & Industry BWC-Administrative Division 1171 S. Cameron St. Harrisburg PA 17104-2501 Essential

More information

Prescription for Disaster: Impact of Drugs in our Society

Prescription for Disaster: Impact of Drugs in our Society Prescription for Disaster: Impact of Drugs in our Society What you can do about the epidemic of drug abuse in our communities 1 Florida Poison Information Center-Tampa 10/26/2012 Cynthia R. Lewis-Younger,

More information

Idaho DUR Board Meeting Minutes

Idaho DUR Board Meeting Minutes Idaho DUR Board Meeting Minutes Date: January 21, 2016 Time: 9am-1:30pm Location: Idaho Medicaid, 3232 Elder Street, Boise, Idaho, Conference Room D-West Moderator: Mark Turner, M.D. Committee Members

More information

Improving Mental Health Care: A Case Study

Improving Mental Health Care: A Case Study Improving Mental Health Care: A Case Study Why Improve Mental Health Care? Because the prevalence and costs of mental health problems are increasing in America despite the high prescribing of psychotropic

More information

Keytruda. Keytruda (pembrolizumab) Description

Keytruda. Keytruda (pembrolizumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 5 Last Review Date: June 24, 2016 Keytruda Description Keytruda (pembrolizumab)

More information

Friend or Foe? Review of the Regulations & Benefits: Risk Profiles of the Benzodiazepines

Friend or Foe? Review of the Regulations & Benefits: Risk Profiles of the Benzodiazepines Friend or Foe? Review of the Regulations & Benefits: Risk Profiles of the Benzodiazepines Program Learning Objectives At the conclusion of the activity, participants should be able to: Have a basic understanding

More information

Today s Presenters. Pills, Providers, and Problems: How to Investigate Drug Diversion in Long-Term Care

Today s Presenters. Pills, Providers, and Problems: How to Investigate Drug Diversion in Long-Term Care Pills, Providers, and Problems: How to Investigate Drug Diversion in Long-Term Care 203 - Monday, April 16, 2018 Today s Presenters Ben Purser Former F.B.I. Special Agent Donna Thiel ProviderTrust Chief

More information

The Louis de la Parte Florida Mental Health Institute

The Louis de la Parte Florida Mental Health Institute Data Brief December 2003 Mary Rose Murrin, M.A. Kelley Dhont, M.S. David Thornton, M.A. The Louis de la Parte Florida Mental Health Institute Children s Psychotropic Medication Use by Age and Diagnostic

More information

Webinar Series: Diabetes Epidemic & Action Report (DEAR) for Washington State - How We Are Doing and How We Can Improve.

Webinar Series: Diabetes Epidemic & Action Report (DEAR) for Washington State - How We Are Doing and How We Can Improve. Webinar Series: Diabetes Epidemic & Action Report (DEAR) for Washington State - How We Are Doing and How We Can Improve April 22, 2015 Qualis Health A leading national population health management organization

More information

USING MTM TO IMPROVE STAR RATINGS : CASE STUDIES

USING MTM TO IMPROVE STAR RATINGS : CASE STUDIES USING MTM TO IMPROVE STAR RATINGS : CASE STUDIES Sept 13, 2015 Amanda Applegate, PharmD, BCACP Disclosures Nothing to disclose Learning Objectives Describe how MTM can improve star ratings Discuss strategies

More information

Cost-Motivated Treatment Changes in Commercial Claims:

Cost-Motivated Treatment Changes in Commercial Claims: Cost-Motivated Treatment Changes in Commercial Claims: Implications for Non- Medical Switching August 2017 THE MORAN COMPANY 1 Cost-Motivated Treatment Changes in Commercial Claims: Implications for Non-Medical

More information

Up to $402,000. Insight HIV. Drug Class. 1.2 million people in the United States were living with HIV at the end of 2011 (most recent data).

Up to $402,000. Insight HIV. Drug Class. 1.2 million people in the United States were living with HIV at the end of 2011 (most recent data). HIV Background, new developments, key strategies Drug Class Insight INTRODUCTION Human Immunodeficiency Virus (HIV) is the virus that can lead to Acquired Immunodeficiency Syndrome, or AIDS. No safe and

More information

About the PCTB Examination Assisting the Pharmacist in Serving Patients p. 1 Filling the Medication Order p. 3 Receiving the Medication Order p.

About the PCTB Examination Assisting the Pharmacist in Serving Patients p. 1 Filling the Medication Order p. 3 Receiving the Medication Order p. Preface p. ix About the PCTB Examination p. xii Assisting the Pharmacist in Serving Patients p. 1 Filling the Medication Order p. 3 Receiving the Medication Order p. 4 The Retail Medication Order p. 6

More information

Cyber Liability and Crime Update

Cyber Liability and Crime Update Cyber Liability and Crime Update Cyber Liability Probability of a Data Breach 2 3 Cyber Liability Challenges Carriers are not as forthcoming with sharing data as we would like to see Large uptick in ransomware

More information

Re: Docket No. FDA-2009-N-0294 Regulation of Tobacco Products; Request for Comments

Re: Docket No. FDA-2009-N-0294 Regulation of Tobacco Products; Request for Comments VIA Electronic Submission to http://www.regulations.gov September 29, 2009 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, rm. 1061 Rockville, MD 20852 Re: Docket

More information

Implementing Pain and Opioid Management Guidelines in Primary Care Practice

Implementing Pain and Opioid Management Guidelines in Primary Care Practice Implementing Pain and Opioid Management Guidelines in Primary Care Practice Objectives 1. What is the issue? 2. Why use a dedicated dissemination & implementation process? a. Historical perspective Cooperative

More information

Update to HMO Drug Formulary Tier Definitions. February 8, 2018

Update to HMO Drug Formulary Tier Definitions. February 8, 2018 Update to HMO Drug Formulary Tier Definitions February 8, 2018 Agenda 1 Overview of Current Drug Tiers 2 Proposed Drug Tiers for 2019 3 Impact to SFHSS and SFHSS Members 4 How the Drug Formulary Works

More information

Module 6: Substance Use

Module 6: Substance Use Module 6: Substance Use Part 1: Overview of Substance Abuse I am Martha Romney and I am presenting on substance abuse. This module focuses on the healthy people 2020 objective to reduce substance abuse

More information

Market Potential for MDX Alcobra Investor Breakfast July 15, 2014

Market Potential for MDX Alcobra Investor Breakfast July 15, 2014 Market Potential for MDX Alcobra Investor Breakfast July 15, 2014 Forward Looking Statement This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases,

More information

Medication trends shaping workers compensation. A 2018 mid-year review of the prevailing industry influences impacting pharmacy outcomes

Medication trends shaping workers compensation. A 2018 mid-year review of the prevailing industry influences impacting pharmacy outcomes Medication trends shaping workers compensation A 2018 mid-year review of the prevailing industry influences impacting pharmacy outcomes OPTUM WORKERS COMPENSATION DATA SET Analysis of our data, the industry

More information

Sanofi Press Breakfast on Behavioral Science. Friday 22 September 2017

Sanofi Press Breakfast on Behavioral Science. Friday 22 September 2017 Sanofi Press Breakfast on Behavioral Science Friday 22 September 2017 Agenda WHY UNDERSTANDING BEHAVIORS CAN UNLOCK CARE SUCCESS 8.45-9.00 Welcome coffee 9.00 Kick-off 9.00-9.10 Introduction by Alexandra

More information

Issues for Part D Compliance

Issues for Part D Compliance HCCA- MEDICARE PRESCRIPTION DRUG PART D COMPLIANCE CONFERENCE Issues for Part D Compliance Craig Miner, RPh, JD Division of Drug Plan Policy Babette S. Edgar, Pharm.D., MBA Division of Finance and Operations

More information

05/01/2014. Medicare has 4 parts A: Hospital coverage National Training Program. Session Objectives. The Basics. B: Outpatient medical coverage

05/01/2014. Medicare has 4 parts A: Hospital coverage National Training Program. Session Objectives. The Basics. B: Outpatient medical coverage 2015 National Training Program Medicare Prescription Drug Coverage Parts A, B and D Session Objectives This session should help you Differentiate when/under what scenarios drugs are covered under the various

More information

Pharmacy Trends and Management Opportunities. Kerry Bendel, R.Ph. Director of Pharmacy Medica

Pharmacy Trends and Management Opportunities. Kerry Bendel, R.Ph. Director of Pharmacy Medica Pharmacy Trends and Management Opportunities Kerry Bendel, R.Ph. Director of Pharmacy Medica September 14, 20 1 Agenda Pharmacy Trend Experience Trend Drivers and Management Opportunities Call to Action

More information

Curbing Prescription Drug Abuse in Medicaid

Curbing Prescription Drug Abuse in Medicaid Curbing Prescription Drug Abuse in Medicaid Joint Legislative Health Care Oversight Committee October 12, 2010 Dr. Lisa Weeks, BSPharm, PharmD Pharmacy and Ancillary Services Division of Medical Assistance

More information

QIOs: Partners for Quality Improvement Under the Medicare Drug Benefit

QIOs: Partners for Quality Improvement Under the Medicare Drug Benefit QIOs: Partners for Quality Improvement Under the Medicare Drug Benefit Presentation to The 2 nd Annual National Medicare Prescription Drug Congress David Schulke Executive Vice President The American Health

More information

Drug Formulary Update, October 2013

Drug Formulary Update, October 2013 Drug Formulary Update, October 2013 Updates to the HealthPartners Drug Formularies are listed below. Updates for the Commercial Drug Formularies and the Minnesota Health Care Programs (Medicaid and Minnesota

More information

HOPE Agenda. Heroin, Opioid Prevention & Education WISCONSIN STATE REPRESENTATIVE JOHN NYGREN ASSEMBLY DISTRICT 89

HOPE Agenda. Heroin, Opioid Prevention & Education WISCONSIN STATE REPRESENTATIVE JOHN NYGREN ASSEMBLY DISTRICT 89 HOPE Agenda Heroin, Opioid Prevention & Education WISCONSIN STATE REPRESENTATIVE JOHN NYGREN ASSEMBLY DISTRICT 89 In compliance with CMA regulation, I attest that I have no conflicts of interest associated

More information

Outpatient use of Atypical Antipsychotic Agents in the Pediatric Population Years

Outpatient use of Atypical Antipsychotic Agents in the Pediatric Population Years Outpatient use of Atypical Antipsychotic Agents in the Pediatric Population Years 2004-2008 Laura Governale, Pharm.D., MBA Team Leader, Drug Utilization Data Analyst Hina Mehta, Pharm.D. Drug Utilization

More information

How Mail-Servi. Prepared for

How Mail-Servi. Prepared for How Mail-Servi ice Pharmacies Will Save $46.6 Billion Over the Next Decade and the Cost of Proposed Restrictions Prepared for February 2012 Table of Contents I. Executive Summary... 3 Major Findings on

More information

PHARMACY BENEFITS MANAGER SELECTION FAQ FOR PRODUCERS

PHARMACY BENEFITS MANAGER SELECTION FAQ FOR PRODUCERS PHARMACY BENEFITS MANAGER SELECTION FAQ FOR PRODUCERS For Producer Audience Only - Please Do Not Distribute Regence has selected Prime Therapeutics as the Pharmacy benefits manager for its health plans.

More information

Keytruda. Keytruda (pembrolizumab) Description

Keytruda. Keytruda (pembrolizumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 6 Last Review Date: September 15, 2017 Keytruda Description Keytruda

More information

CONFRONTING THE OPIOID EPIDEMIC. e-book: Introducing OptumRx Opioid Risk Management

CONFRONTING THE OPIOID EPIDEMIC. e-book: Introducing OptumRx Opioid Risk Management CONFRONTING THE OPIOID EPIDEMIC 2 0 1 8 OPIOID ABUSE IS A CRISIS IN THE U.S. OptumRx Opioid Risk Management attacks this complex, deeply embedded problem with a comprehensive approach featuring five interrelated

More information

29 August 2016 Page 1 of 7. How does the NHS board decide which new medicines to make available for patients?

29 August 2016 Page 1 of 7. How does the NHS board decide which new medicines to make available for patients? NHS Greater Glasgow and Clyde: New Medicines Decisions In Scotland, a newly licensed medicine is routinely available for use in an NHS board only after it has been: accepted for use in the NHSScotland

More information

Understanding Hierarchical Condition Categories (HCC)

Understanding Hierarchical Condition Categories (HCC) Understanding Hierarchical Condition Categories (HCC) How hierarchical condition category coding will impact your practice and how you can use these codes to increase quality, improve the patient experience,

More information

ATS 2013 International Conference May Philadelphia Pennsylvania

ATS 2013 International Conference May Philadelphia Pennsylvania American Journal of Respiratory and Critical Care Medicine American Journal of Respiratory Cell and Molecular Biology Proceedings of the American Thoracic Society STEPHEN C. CRANE, PhD, MPH Executive Director

More information

Medicare Advantage Outreach and Education Bulletin

Medicare Advantage Outreach and Education Bulletin Medicare Advantage Outreach and Education Bulletin Blue Cross and Blue Shield of Georgia Prescription Drug Monitoring Programs Prescription drug abuse and diversion are acute problems in the area of pain

More information

California Workers Compensation Prescription Drug Utilization & Payment Distributions, : Part 1

California Workers Compensation Prescription Drug Utilization & Payment Distributions, : Part 1 California Workers Compensation Prescription Drug Utilization & Payment Distributions, 2009-2018: Part 1 Bob Young and Steve Hayes Background Over the past two decades, public policymakers in California

More information

Managed Care Trends in Statin Usage GARY R. BAZALO, MS, MBA

Managed Care Trends in Statin Usage GARY R. BAZALO, MS, MBA PHARMACY UTILIZATION Managed Care Trends in Statin Usage GARY R. BAZALO, MS, MBA ABSTRACT Purpose HMG-CoA reductase inhibitors ( statins ) have become the drug class of choice for the treatment of hyperlipidemia.

More information

Minimizing Rx Opioid Fraud and Abuse While Maintaining Appropriate Access for Patients In Need. Best Practices for Rx Payers

Minimizing Rx Opioid Fraud and Abuse While Maintaining Appropriate Access for Patients In Need. Best Practices for Rx Payers Minimizing Rx Opioid Fraud and Abuse While Maintaining Appropriate Access for Patients In Need Best Practices for Rx Payers William J. Mahon The MAHON Consulting Group LLC THCI Program on Opioid Risk Management

More information